Core One Labs (COOL.C) reported today that they’re ready to start biosynthetic production trials with psilocybin, according to a press release. The company’s Victoria-based subsidiary, Vocan Biotechnologies, finished developing…
Psychedelics
For a year, naysayers have dismissed the early stage shroom boom as being a pumpy bunch of pubco RTOs that won’t be able to do business legally for years….
Schizophrenia In January, the Berlin-based psychedelics giant ATAI Life Sciences purchased a majority stake in Recogify – a company researching drugs to combat ailments associated with schizophrenia. The…
IPO’s come in all shapes and sizes, some are giants with billionaire support, and others don’t have a pitch deck readily available. Investors get giddy with news of…
Cut the kumbaya shit Throwing the words profit and psychedelic drugs into a sentence would have lead to awkward and confused looks 5 years ago. But we have come…
Numinus Wellness’ (NUMI.V) compassionate-access trial for MDMA-assisted therapy has enjoyed some success in terms of treating patients with post-traumatic stress disorder (PTSD), according to a press release. The trial…
Mind Medicine (MMED.E) announced today their intended acquisition of digital medicine and therapeutics start-up, Healthmode, according to a press release. The acquisition brings access to HealthMode’s intellectual property, as…
Algernon Pharmaceuticals (AGN.C) awarded the contract for the synthesis and manufacture of the psychoactive ingredient and finished product for its AP-188 DMT project to Canadian-based Dalton Pharma Services today,…
Brazil Red Light Holland (TRIP.CN) is going in the opposite direction of most of the psychedelics space. It’s a gamble, but if it works it pays off. …
New Wave Holdings’ (SPOR.C) recent acquisition Way of Will completed the expansion of their Toronto-based facility, today, according to a press release. Way of Will expanded their production facility…